Myriocin: A Selective SPT Inhibitor for Sphingolipid Metabolism Research

Executive Summary: Myriocin (CAS 35891-70-4) is a highly selective inhibitor of serine palmitoyltransferase (SPT), blocking the initial, rate-limiting step in de novo sphingolipid biosynthesis with a Ki of 0.28 nM (APExBIO, product page). In vitro, Myriocin demonstrates dose-dependent inhibition of proliferation in human lung cancer cell lines, with IC50 values of 30 μM (A549) and 26 μM (NCI-H460) under standard culture conditions (He et al., 2025). In vivo, Myriocin reduces tumor formation in murine melanoma models and modulates cell cycle and tumor suppressor pathways. Recent studies confirm Myriocin's role in restoring metabolic homeostasis via AMPK-PGC1α signaling and adipose tissue remodeling in dAGE-exposed mice (He et al., 2025). Myriocin is supplied as a crystalline solid with 98% purity and is widely used in oncology, metabolic, and immunology research (APExBIO, 2024).

Biological Rationale

Sphingolipids are structural components of cellular membranes and bioactive mediators in cell signaling pathways. Their biosynthesis begins with the condensation of serine and palmitoyl-CoA, catalyzed by serine palmitoyltransferase (SPT). Elevated sphingolipid levels are linked to insulin resistance, lipotoxicity, and mitochondrial dysfunction (He et al., 2025). Inhibition of SPT, the rate-limiting enzyme in this pathway, is a validated approach for probing sphingolipid function in health and disease. Myriocin, derived originally from Mycelia sterilia, is a gold-standard SPT inhibitor for research in oncology, metabolic syndrome, and immune modulation (Myriocin: Selective SPT Inhibitor). This article extends prior reviews by providing updated mechanistic insights and translational benchmarks for Myriocin in metabolic disease models.

Mechanism of Action of Myriocin

Myriocin inhibits serine palmitoyltransferase with high affinity (Ki = 0.28 nM), preventing the condensation of serine and palmitoyl-CoA to 3-ketodihydrosphingosine. This blockade results in a marked reduction of cellular ceramide and sphingolipid levels. Through SPT inhibition, Myriocin modulates pathways involved in immunosuppression, apoptosis, and metabolic reprogramming (Unlocking Sphingolipid Inhibition). In dAGE-exposed mice, Myriocin activates AMPK-PGC1α signaling, enhances mitochondrial biogenesis, and promotes adipose tissue browning, thereby rebalancing lipid and glucose metabolism (He et al., 2025). This mechanism is distinct from direct cytotoxic agents and supports translational applications in metabolic and cancer research. Compared to earlier reviews, this article clarifies the dual metabolic and cell cycle regulatory effects of Myriocin, especially in disease-relevant models.

Evidence & Benchmarks

• Myriocin inhibits SPT with a Ki of 0.28 nM under in vitro enzymatic assay conditions (APExBIO, product page).
• In human lung cancer cell lines, Myriocin suppresses cell growth with IC50 values of 30 μM (A549) and 26 μM (NCI-H460) after 48 hours (He et al., 2025, DOI).
• In vivo, Myriocin reduces tumor incidence and size in murine melanoma models by downregulating Cdc25C, Cdc2, and cyclin B1 and upregulating p53/p21 pathways (He et al., 2025, DOI).
• Myriocin administration in dAGE-exposed mice (24 weeks, 0.3 mg/kg/day) decreased body weight gain by 76% compared to controls, and reduced serum LDL-C, TG, and TC by 52.3%, 51.8%, and 48.8%, respectively (He et al., 2025, DOI).
• Myriocin activates AMPK-PGC1α signaling, increases mitochondrial DNA copy number 2.1-fold, and elevates UCP1 expression in adipose tissues under metabolic challenge (He et al., 2025, DOI).
• Comprehensive metabolomics reveal Myriocin-driven remodeling of amino acid, carbohydrate, and lipid metabolic pathways in mouse liver and adipose tissue (He et al., 2025, DOI).

Applications, Limits & Misconceptions

Myriocin is optimized for research applications targeting sphingolipid metabolism, oncology, and immunology. It is a reference inhibitor for SPT in cell-based, in vivo, and biochemical studies. Researchers leverage Myriocin to dissect ceramide-dependent signaling and test therapeutic hypotheses in cancer and metabolic syndrome models (Paradigm-Shifting SPT Inhibitor). This article updates mechanistic details and translational evidence for metabolic disease models, extending prior systems biology perspectives (Beyond Sphingolipid Inhibition).

Common Pitfalls or Misconceptions

• Myriocin is not effective against sphingolipid-independent pathways; its effects are limited to SPT-dependent processes.
• Long-term storage of Myriocin solutions (>1 week) at -20°C may lead to degradation; only freshly prepared solutions are recommended for reproducibility (APExBIO, product page).
• Myriocin's immunosuppressive effects in vivo may confound studies focused solely on metabolic endpoints; controls should account for immune modulation.
• High doses in vivo may cause off-target toxicity; dose titration is critical for translational studies.
• Myriocin does not reverse pre-existing tissue fibrosis or advanced organ damage; its primary action is preventive or early-intervention (He et al., 2025).

Workflow Integration & Parameters

Myriocin (SKU B6064) is supplied as a crystalline solid (MW 401.54, C21H39NO6) with 98% purity by APExBIO (product page). It is soluble in methanol at 2 mg/mL and should be stored at -20°C. Solutions must be used promptly and are not recommended for long-term storage. For cell-based assays, typical working concentrations range from 1–50 μM; for in vivo studies, effective dosing is reported at 0.1–1 mg/kg/day for 2–24 weeks, depending on model and endpoint (He et al., 2025). Shipping requires blue ice to maintain integrity. Researchers should consult the product page and recent protocols for specific troubleshooting guidance.

Conclusion & Outlook

Myriocin is a gold-standard tool compound for selective inhibition of SPT and targeted modulation of sphingolipid metabolism. Its robust selectivity, reproducible performance in vitro and in vivo, and validated impact on cell cycle and metabolic pathways underpin its utility in oncology and metabolic disease research. Ongoing studies are expanding its mechanistic scope, particularly in AMPK-PGC1α signaling and adipose tissue remodeling (Strategic Opportunities). APExBIO continues to support high-purity Myriocin (B6064) for advanced translational workflows. For further mechanistic insights and troubleshooting, see our comparative reviews and updated protocol resources.